Novo Nordisk lands €4bn multi-part deal through fair value
◆ Good reception for new bonds despite company profit downgrade ◆ Negative premium on all legs ◆ Longest maturity draws biggest book
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: